

**Placement cleansing notice under section 708A(5)(e) Corporations Act – Tissue Therapies Limited (trading as Factor Therapeutics)  
(ASX Code: TIS)**

Tissue Therapies Limited ACN 101 955 088 trading as Factor Therapeutics (ASX:TIS) (**Factor**) has today issued 194,290,000 fully paid ordinary shares at a price of \$0.035 to raise approximately \$6.8 million (**Shares**) by way of a placement to institutional and sophisticated investors (**Placement**), as outlined in Factor's announcement on 18 March 2016.

Factor has issued the shares without disclosure to investors under section 708A(5) *Corporations Act 2001* (Cth) (**Corporations Act**).

**Details of securities issued**

<b>Class of securities:</b>	Ordinary shares
<b>ASX Code of the securities:</b>	TIS
<b>Date of the issue of the securities:</b>	4 May 2016
<b>Total number of securities issued:</b>	194,290,000

For the purposes of section 708A(6) Corporations Act, Factor advises that:

- 1 the Shares have been issued without disclosure to investors under Part 6D.2 Corporations Act;
- 2 this notice is given under section 708A(5)(e) Corporations Act;
- 3 as at the date of this notice, Factor has complied with:
  - (a) the provisions of Chapter 2M Corporations Act as they apply to Factor; and
  - (b) section 674 Corporations Act; and
- 4 as at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) Corporations Act to be disclosed under section 708A(6)(e) Corporations Act.

For and on behalf of the Board of Factor.



**Saskia Jo**  
**Company Secretary**  
**Tissue Therapies Limited (trading as Factor Therapeutics)**

## **Corporate Contact**

Dr. Christian P. Behrenbruch  
Executive Director  
Tissue Therapies Limited, trading as Factor Therapeutics  
Tel: +61 7 3334 3900  
Email: [c.behrenbruch@factor-therapeutics.com](mailto:c.behrenbruch@factor-therapeutics.com)

## **About Factor Therapeutics**

Tissue Therapies Limited (trading as Factor Therapeutics) is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. Factor Therapeutics is commercialising VF-001 (previously denoted VitroGro® ECM), a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The business owns various patent families related to wound healing and other therapeutic uses. The Company's shares are traded on the Australian, Berlin and Frankfurt stock exchanges. For more information, please visit [www.factor-therapeutics.com](http://www.factor-therapeutics.com)

## **Important information**

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the 'US Securities Act'), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. This document may not be distributed or released in the United States.